Comparative efficacy and safety of dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes mellitus: A network meta‐analysis
Pooled result · HbA1cResult — go to the resultMD −0.81 % 95% CI −1.03 to −0.60Authors' conclusion
In adults with type 2 diabetes, teneligliptin was most effective for HbA1c control, and vildagliptin for fasting blood glucose. No significant differences in serious adverse events were noted among DPP-4 inhibitors compared to placebo. Given the therapeutic significance of these findings, more studies are needed to explore this issue more thoroughly.
Study context
- Population
- Adults with T2D treated with DPP-4 inhibitors; PubMed, Embase, Cochrane Library and ClinicalTrials.gov searched to 20 May 2024
- Participants
- 21,332 adults58 studies
- Comparison
- DPP-4 inhibitors vs each other and vs placebo
- Outcome
- HbA1c
Methodological detailsfrequentist framework, P-score ranking
- Frequentist framework
- P-score ranking
Pooled result
As reported in the abstract
MD
−0.81 %
95% CI −1.03 to −0.60
Teneligliptinvs Placebo
MD −0.81 % (95% CI −1.03 to −0.60)
Further pooled results
| Outcome | MD (mmol/L) (95% CI) | |
|---|---|---|
| Fasting blood glucoseVildagliptinvs PlaceboModerate certainty; superior to all other DPP-4 inhibitors | −1.18 (−1.56 to −0.81) | |
| −2−101Difference, mmol/L (linear scale) |
Safety
- No conclusive differences between interventions for serious adverse events
- Low to very low certainty
Original publication
Comparative efficacy and safety of dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes mellitus: A network meta‐analysis. Diabetes Obes Metab. Published 6 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →